News >

Three Biosimilars Entering US Oncology Market at Substantial Discounts

Kristi Rosa
Published: Thursday, Jan 23, 2020

Mark D. Pegram, MD, associate director for clinical research, Stanford Comprehensive Cancer Institute

Mark D. Pegram, MD

Three biosimilars—bevacizumab-bvzr (Zirabev), rituximab-pvvr (Ruxience), and trastuzumab-qyyp (Trazimera)—will become available in the United States at a substantial discount to their reference products bevacizumab (Avastin), rituximab (Rituxan), and trastuzumab (Herceptin), respectively, according to an announcement made by Pfizer.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication